AbbVie Highlights First Patient Dosed In Global Phase 3 Trial Of Upadacitinib In Hidradenitis Suppurativa
Portfolio Pulse from Benzinga Newsdesk
AbbVie has announced that the first patient has been dosed in a global Phase 3 trial of Upadacitinib for Hidradenitis Suppurativa. This marks a significant step in the development of the drug.
July 24, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's dosing of the first patient in a global Phase 3 trial of Upadacitinib marks a significant milestone in the drug's development. This could potentially impact the company's stock positively in the short term.
The initiation of a Phase 3 trial is a significant step in drug development, indicating that the drug has shown promise in earlier trials. This news could potentially boost investor confidence in AbbVie, leading to a positive impact on the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100